Last updated: September 3, 2026
Pegulicianine acetate, commercialized in the United States as Lumisight, is an FDA-approved fluorescent imaging agent used with the Lumicell Direct Visualization System during breast-conserving surgery. Its commercial opportunity is concentrated in intraoperative margin assessment for breast cancer rather than systemic oncology treatment.
The product has a differentiated regulatory position, but its financial trajectory depends on adoption by breast surgeons, hospital capital-equipment purchasing, reimbursement, procedure-level economics, and clinical evidence showing reduced re-excision rates. Lumicell is privately held and has not publicly disclosed product revenue, pricing, operating margins, or a detailed launch forecast. Public data support a commercial ramp thesis, but not a precise revenue estimate.
What is pegulicianine acetate and how is it used?
Pegulicianine is a fluorescent imaging agent that is administered intravenously before breast-conserving surgery. The agent is designed to accumulate in tumor-associated tissue and produce fluorescence when activated in the tumor microenvironment. The Lumicell Direct Visualization System detects the fluorescence in tissue surrounding the surgical cavity.
The FDA indication covers adult women with breast cancer undergoing lumpectomy as an adjunct to identify cancerous tissue within the breast-conserving surgery cavity. It does not replace standard pathology and is not a standalone diagnostic test. [1]
| Product attribute |
Publicly reported position |
| Commercial product |
Lumisight |
| Active agent |
Pegulicianine |
| Salt designation |
Pegulicianine acetate |
| Sponsor |
Lumicell, Inc. |
| Delivery |
Intravenous injection |
| Use |
Intraoperative visualization during breast-conserving surgery |
| Companion technology |
Lumicell Direct Visualization System |
| Regulatory pathway |
FDA drug-device combination product |
| Therapeutic category |
Surgical imaging and margin assessment |
| Primary commercial market |
U.S. breast-conserving surgery |
The FDA prescribing information identifies a recommended dose of 1 mg/kg administered intravenously before surgery, with imaging performed during the surgical procedure. The product carries warnings related to hypersensitivity reactions and false-positive or false-negative fluorescence findings. [1]
When did Lumisight receive FDA approval?
The FDA approved Lumisight and the Lumicell Direct Visualization System in 2024. The approval created a commercial pathway for an integrated drug-device platform rather than a conventional pharmaceutical launch. [2]
The approval is strategically important because the drug and imaging system are operationally linked. Hospitals must evaluate the recurring injectable product and the associated visualization equipment as a combined workflow.
FDA regulatory status
| Regulatory issue |
Status |
| FDA approval |
Approved in 2024 |
| Indication |
Adjunctive visualization of cancerous tissue during breast-conserving surgery |
| Product type |
Fluorescent imaging agent |
| Device dependency |
Yes |
| Replacement for histopathology |
No |
| Approved use in metastatic disease |
No |
| Approved use across all solid tumors |
No |
| Approved use in mastectomy |
No, based on the labeled breast-conserving-surgery indication |
The label limits the near-term addressable market to procedures in which the surgeon creates a breast-conserving surgery cavity and can use intraoperative imaging to assess residual tissue. Expansion into other cancers or procedures would require additional clinical and regulatory work.
How large is the pegulicianine acetate market opportunity?
The commercial market is tied to annual breast-conserving surgery volume, not the total breast cancer population. The relevant addressable population includes patients who undergo lumpectomy and whose treating institutions can support the required imaging workflow.
Market penetration will be determined by five factors:
- The number of breast-conserving procedures performed annually.
- The percentage of hospitals with access to the Lumicell visualization system.
- Surgeon confidence in fluorescence results.
- The effect on positive-margin and re-excision rates.
- Hospital and payer willingness to absorb the combined drug, device, staffing, and operating-room costs.
The product has a focused market but a potentially repeatable procedure-based revenue model. Each treated case can generate recurring drug revenue after the hospital has adopted the visualization system. The installed device base can therefore act as a commercial multiplier for future Lumisight sales.
Market expansion potential
The most credible expansion routes are:
- Increased penetration in U.S. breast-conserving surgery.
- Use in additional breast cancer subtypes or surgical settings.
- Expansion into other solid tumors where tumor-associated protease activity can produce useful signal.
- Additional imaging applications supported by new clinical trials.
- International regulatory approvals.
- Partnerships with surgical equipment companies or oncology-focused pharmaceutical companies.
Expansion beyond breast-conserving surgery would materially increase the opportunity but should not be included in a base-case valuation until supported by regulatory approvals and clinical data.
What drives the financial trajectory for Lumisight?
Lumisight’s financial trajectory should be modeled as an adoption-led medical technology launch rather than a conventional high-volume prescription drug launch.
A simplified revenue framework is:
Revenue = eligible procedures × adoption rate × cases per account × net price per case
The most important operating variables are account acquisition, utilization per installed system, repeat procedure volume, and net realized price.
| Financial driver |
Near-term effect |
Longer-term effect |
| Device placement |
Increases hospital access |
Creates recurring procedure capacity |
| Surgeon training |
Slows early adoption |
Improves utilization and retention |
| Reimbursement |
Determines hospital economics |
Supports broader standard-of-care adoption |
| Clinical evidence |
Influences purchasing decisions |
Supports guideline and payer acceptance |
| Manufacturing scale |
Affects gross margin |
Can improve unit economics |
| International approvals |
Limited initial contribution |
Expands procedure base |
| New indications |
High development cost |
Could materially expand revenue |
The initial financial profile is likely to include high commercial expenses. Lumicell must support capital equipment placement, field service, operating-room education, clinical evidence generation, regulatory compliance, and hospital contracting. Gross margin on the injectable product may improve with manufacturing scale, but early profitability can remain pressured by low utilization per installed system.
Is pegulicianine acetate generating disclosed revenue?
No public, audited product revenue figure has been disclosed in the principal public sources available for Lumicell. The company is privately held and does not provide the recurring quarterly financial reporting required of a publicly traded pharmaceutical company.
Publicly available information does not establish:
- Net sales by quarter or year.
- Product launch price.
- Gross margin.
- Number of installed Lumicell systems.
- Number of Lumisight-treated procedures.
- U.S. sales force size.
- Commercial break-even date.
- Cash runway.
- Product-level operating expenses.
- Royalty obligations or milestone payments.
The absence of disclosed revenue does not establish weak demand. It means the company’s financial trajectory cannot be measured through public income statements. Commercial diligence should therefore focus on hospital placements, utilization, reimbursement, procedure volumes, and evidence of re-excision reduction.
How does the competitive landscape compare with Lumisight?
Lumisight competes with existing surgical and pathology workflows rather than with one directly interchangeable drug.
| Competitive approach |
Primary function |
Commercial advantage |
Limitation relative to Lumisight |
| Intraoperative pathology |
Margin assessment |
Established clinical practice |
Can add time and operating-room complexity |
| Postoperative pathology |
Definitive margin evaluation |
Required standard of care |
Results may require a second procedure |
| Specimen radiography |
Confirms excision of targeted lesions |
Widely used in breast surgery |
Does not directly provide fluorescence-based cavity imaging |
| Surgical judgment and visual inspection |
Immediate intraoperative assessment |
No added drug cost |
Limited sensitivity for occult residual disease |
| Lumisight plus Lumicell DVS |
Fluorescent cavity visualization |
Provides an additional intraoperative signal |
Requires drug, device, training, and workflow integration |
| Pafolacianine |
Fluorescent imaging in selected ovarian cancer surgery |
Validated fluorescent imaging platform in another indication |
Not a direct substitute for the breast-cancer indication |
The strongest commercial argument is a potential reduction in positive margins and repeat operations. The strongest commercial barrier is that hospitals may view Lumisight as an incremental cost unless clinical and health-economic data show measurable savings or improved outcomes.
What generic entry risks exist for pegulicianine acetate?
Generic entry risk is lower than for a conventional oral small-molecule drug because Lumisight is used with a proprietary or specialized imaging system and requires procedure-level workflow adoption.
Potential entry routes include:
- An ANDA for the drug product, if the product and device requirements can be adequately addressed.
- A 505(b)(2) application relying partly on existing data.
- A competing fluorescent imaging agent with a different mechanism.
- A competing imaging device paired with a new agent.
- Hospital-level substitution if a rival platform demonstrates equivalent clinical utility.
The device dependency raises practical barriers, but it does not eliminate pharmaceutical competition. A rival agent could target the same surgical problem without copying the exact molecular structure.
Paragraph IV challenges and patent litigation
No publicly established Paragraph IV challenge, FDA patent-certification dispute, or major patent litigation involving pegulicianine acetate is identified in the core public approval materials cited here. The product’s litigation exposure cannot be quantified from the FDA label alone.
The relevant legal protections are likely to include several layers:
- Composition-of-matter patents covering the imaging agent.
- Conjugate or linker patents.
- Tumor-activated imaging chemistry.
- Methods of detecting residual cancerous tissue.
- Combination claims covering the agent and visualization system.
- Manufacturing and formulation know-how.
- Regulatory exclusivity associated with the approved product.
A competitor could attempt to design around composition claims while pursuing similar method-of-use claims. The commercial importance of device integration may therefore be comparable to the strength of the drug patent estate.
What patents protect pegulicianine acetate?
Public FDA materials do not provide a complete, authoritative list of all patent rights covering pegulicianine acetate, the Lumisight formulation, or the Lumicell imaging system. Patent protection should be assessed across the drug, device, use, and manufacturing layers rather than through a single patent number.
The most important diligence questions are:
| Patent category |
Commercial relevance |
| Active-agent composition |
Can block direct chemical copies |
| Fluorophore and linker structure |
May protect design architecture |
| Tumor-activated mechanism |
Can limit competing use claims |
| Formulation and injectable stability |
Can delay practical substitution |
| Imaging-system integration |
Can restrict use of the approved workflow |
| Surgical method claims |
May cover intraoperative margin assessment |
| Manufacturing process |
Can increase cost and technical barriers for entrants |
Orange Book status and exclusivity
The Orange Book position should be verified against the current FDA publication for the applicable NDA. Public approval documents establish FDA approval but do not, by themselves, establish the complete set of listed patents or the precise generic-entry date.
Pegulicianine is also not a biologic. Biosimilar competition is therefore not the relevant pathway. The principal regulatory risks are a generic or 505(b)(2) application, a competing imaging agent, and device-linked design-around strategies.
When does pegulicianine acetate lose exclusivity?
A definitive loss-of-exclusivity date cannot be calculated from the approval date alone. The date depends on:
- The effective FDA approval date.
- Whether the product received new chemical entity exclusivity.
- Any patent term adjustment or patent term extension.
- Listed patents and their expiration dates.
- Pediatric exclusivity.
- The legal pathway used by a challenger.
- Litigation settlements or other agreements.
The FDA approval itself creates regulatory exclusivity only if the product qualifies under the relevant statutory category. A drug-device combination does not automatically produce a single exclusivity period that controls every component.
No publicly documented settlement agreement with a generic challenger is established in the cited sources. No biosimilar settlement is relevant because pegulicianine is a small-molecule imaging agent.
What licensing deals affect pegulicianine acetate?
Public FDA documents do not establish a complete licensing or royalty history for pegulicianine acetate. The commercial structure should be analyzed for rights to:
- The active fluorophore.
- Tumor-activated peptide or linker technology.
- Manufacturing processes.
- The Lumicell visualization system.
- International commercialization.
- Co-development or co-promotion.
An undisclosed royalty burden could reduce product gross margin even if procedure volumes grow. Conversely, an exclusive commercial partnership could accelerate hospital access while reducing Lumicell’s retained economics.
What generic launch scenarios are most likely?
Scenario 1: Controlled U.S. specialty launch
Lumicell places systems in selected breast centers and concentrates on high-volume surgeons. Revenue grows gradually, with early emphasis on evidence generation and hospital reference accounts. This is the most conservative commercial path.
Scenario 2: Evidence-led adoption
Clinical or health-economic results demonstrate fewer positive margins, fewer re-excisions, or lower total episode costs. Hospitals expand use across breast programs, increasing recurring Lumisight demand.
Scenario 3: Partnership-led expansion
A larger pharmaceutical, diagnostics, or surgical-device company provides distribution, capital, and international commercialization. This could improve scale but would likely reduce Lumicell’s share of economics.
Scenario 4: Competitive displacement
A rival imaging agent or device offers lower cost, easier workflow, stronger signal, or broader indications. Lumisight remains clinically differentiated but achieves limited utilization.
How strong is the commercial patent and market position?
Lumisight has a credible first-mover position in FDA-approved fluorescent margin visualization for breast-conserving surgery. Its commercial defensibility depends on more than molecular patents.
The strongest barriers are likely to be:
- FDA approval for a defined surgical indication.
- Integration of the drug with a specialized imaging device.
- Surgeon and hospital workflow training.
- Clinical evidence and institutional familiarity.
- Manufacturing know-how.
- Reimbursement and contracting infrastructure.
The main vulnerabilities are the narrow initial indication, absence of publicly disclosed revenue traction, dependence on hospital adoption, and possible competition from alternative imaging platforms.
Key Takeaways
- Pegulicianine acetate is commercialized as Lumisight, an FDA-approved fluorescent imaging agent used with the Lumicell Direct Visualization System.
- Its initial market is breast-conserving surgery, with revenue tied to procedure volume and hospital adoption.
- The business model combines recurring drug sales with capital-equipment placement and service requirements.
- Lumicell has not publicly disclosed product revenue, pricing, installed systems, or profitability.
- Generic risk is moderated by device dependence and workflow integration, but competing imaging agents remain a material threat.
- Biosimilar risk does not apply.
- A definitive patent expiration or loss-of-exclusivity date cannot be established from the FDA label alone.
- Commercial upside depends most heavily on evidence showing reduced re-excision rates, favorable health economics, and repeat use by high-volume breast centers.
FAQs
Is pegulicianine acetate the same product as Lumisight?
Yes. Lumisight is the commercial name for the pegulicianine fluorescent imaging product approved for use during breast-conserving surgery.
Is Lumisight a treatment for breast cancer?
No. Lumisight is an adjunctive imaging agent. It helps surgeons visualize tissue during surgery and does not treat breast cancer or replace histopathological analysis.
Can hospitals use Lumisight without the Lumicell imaging system?
The approved commercial workflow is designed for use with the Lumicell Direct Visualization System. The drug-device combination is central to the product’s regulatory and commercial model.
Does pegulicianine acetate have biosimilar competition?
No. Pegulicianine is a small-molecule imaging agent, so biosimilar regulations do not apply. Potential competition would more likely come from generic, 505(b)(2), or alternative fluorescent imaging products.
What evidence would most improve the Lumisight financial outlook?
Evidence of lower positive-margin rates, fewer repeat breast surgeries, favorable hospital economics, strong per-system utilization, and broad payer support would provide the clearest basis for a higher commercial forecast.
References
- U.S. Food and Drug Administration. (2024). Lumisight (pegulicianine) injection prescribing information.
- U.S. Food and Drug Administration. (2024). FDA approves imaging drug and device to help identify cancerous tissue during breast cancer surgery.
- ClinicalTrials.gov. (2024). Study of pegulicianine fluorescence imaging in breast-conserving surgery. National Library of Medicine.